Last reviewed · How we verify

AKR 202 — Competitive Intelligence Brief

AKR 202 (AKR 202) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K/mTOR inhibitor. Area: Oncology.

phase 2 PI3K/mTOR inhibitor PI3K/AKT/mTOR pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AKR 202 (AKR 202) — Akron Molecules AG. AKR 202 is a small molecule that targets the PI3K/AKT/mTOR pathway.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AKR 202 TARGET AKR 202 Akron Molecules AG phase 2 PI3K/mTOR inhibitor PI3K/AKT/mTOR pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K/mTOR inhibitor class)

  1. Advagene Biopharma Co. Ltd. · 1 drug in this class
  2. Akron Molecules AG · 1 drug in this class
  3. Allgenesis Biotherapeutics Inc. · 1 drug in this class
  4. Arcus Biosciences, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AKR 202 — Competitive Intelligence Brief. https://druglandscape.com/ci/akr-202. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: